Results 311 to 320 of about 159,964 (350)
Some of the next articles are maybe not open access.
Risk Factors for Biliary Tract Cancers
American Journal of Gastroenterology, 1999 Little is known regarding risk factors for biliary tract cancer, i.e., gallbladder carcinoma and extrahepatic bile duct carcinoma. This is the first case-control study conducted in the U.S. regarding risk factors for these cancers.In this hospital-based case-control study, we reviewed the medical records of 69 patients with primary biliary tract cancer Z R, Khan, A I, Neugut, H, Ahsan, J A, Chabot +3 moreopenaire +2 more sourcesMolecular pathology of biliary tract cancers
Cancer Letters, 2007 The molecular mechanisms underlying the development, growth and metastatic diffusion of biliary tract cancers are still undefined. The increase in worldwide incidence and mortality of cholangiocarcinoma justifies the impellent need to clarify the intracellular mechanisms triggering the malignant transformation of the biliary epithelium and growth of ...Giammarco, Fava, Marco, Marzioni, Antonio, Benedetti, Shannon, Glaser, Sharon, DeMorrow, Heather, Francis, Gianfranco, Alpini +6 moreopenaire +2 more sourcesNonsurgical therapy of biliary tract cancer
Current Opinion in Gastroenterology, 2011 The management of biliary tract cancers (BTCs) has been challenging partly because of the lack of robust data to define a treatment standard. This in turn has been because of the difficulty in conducting large clinical studies in an uncommon cancer, as well as managing elderly and unwell patients.Recent data and improvements in multidisciplinary ...Ignacio, Vazquez, John, Bridgewateropenaire +2 more sourcesAdjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet, 2023 K. Nakachi, M. Ikeda, M. Konishi, S. Nomura, H. Katayama, T. Kataoka, A. Todaka, H. Yanagimoto, S. Morinaga, Shogo Kobayashi, K. Shimada, Y. Takahashi, T. Nakagohri, K. Gotoh, K. Kamata, Yasuhiro Shimizu, M. Ueno, H. Ishii, T. Okusaka, J. Furuse, Keiya Okamura, Y. Kawamoto, A. Katanuma, M. Unno, H. Shirakawa, Hironori Yamaguchi, Amane Takahashi, H. Yanagibashi, Naoya Kato, Y. Sakamoto, Y. Kojima, R. Higuchi, N. Sasahira, K. Sano, Y. Sunakawa, Y. Kumamoto, K. Sugimori, T. Nomura, K. Shibuya, I. Makino, K. Yamazaki, N. Mizuno, H. Wada, M. Sekimoto, T. Ajiki, I. Nakamura, I. Miki, Hiroaki Nagano, K. Ohta, T. Okabayashi, M. Furukawa, N. Fujimori +51 moresemanticscholar +1 more sourceGemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
The Lancet Gastroenterology and Hepatology, 2022 D. Oh, Kyung-Hun Lee, Dae-Won Lee, Jeesun Yoon, Tae-Yong Kim, J. Bang, Ah-Rong Nam, K. Oh, Jae-Min Kim, Young S. Lee, V. Guthrie, P. McCoon, Weimin Li, Song Wu, Qu Zhang, M. Rebelatto, J. W. Kim +16 moresemanticscholar +1 more sourcePertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
The Lancet Oncology, 2021 M. Javle, M. Borad, N. Azad, R. Kurzrock, G. Abou-Alfa, B. George, J. Hainsworth, F. Meric-Bernstam, C. Swanton, C. Sweeney, C. Friedman, R. Bose, D. Spigel, Yong Wang, Jonathan Levy, K. Schulze, V. Cuchelkar, Arisha Patel, H. Burris +18 moresemanticscholar +1 more source
